PT - JOURNAL ARTICLE AU - McColl, Lewis AU - Strassheim, Victoria AU - Linsley, Matthew AU - Green, David AU - Dunkel, Charlotte AU - Trundle, Heidi AU - Gibbon, Jake R AU - Parry, Steve W TI - Falls Efficacy Scale International (FES-I) as a predictor of gait and balance abnormalities in community dwelling older people AID - 10.1101/2022.09.29.22280485 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.29.22280485 4099 - http://medrxiv.org/content/early/2022/09/30/2022.09.29.22280485.short 4100 - http://medrxiv.org/content/early/2022/09/30/2022.09.29.22280485.full AB - Background Fear of falling (FoF) is common amongst community-dwelling older adults and is associated with higher falls risk. FoF is common amongst those with gait and balance abnormalities (GABAb), yet the ability of FoF measures to predict GABAb has not been assessed.Methods Data were reviewed from attendees of the North Tyneside Community Falls Prevention Service. The Falls Efficacy Scale International (FES-I) was used to measure falls efficacy, with a score larger than 23.5 indicating a concern for falling. Gait and balance measures were assessed, with cut-offs used to indicate poor and non-poor results for timed up and go (TUG) (>14s), five times sit to stand (FTSS) (>15s) and gait speed (GS) (<1 m/s). Receiver operating characteristic curves were generated for sensitivity and specificity analysis.Results FES-I score had good to excellent sensitivity when predicting TUG (87.1%), FTSS (82.9%) and GS results (73.0%) indicative of significant GABAb. Moderate specificity was also observed when predicting GS (62%) and FTSS (62.3%); a low to moderate specificity was observed when predicting TUG (50.0%).Conclusion A FES-I score of 23.5 or more showed high specificity in identifying those with prolonged TUG and FTSS and slower GS, with moderate specificity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Caldicott approvals were locally granted, while ethical approval was confirmed as not required by North of England Commissioning Service given the routine anonymised clinical data collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors